{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:41:51Z","timestamp":1762875711396},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T00:00:00Z","timestamp":1437782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grant-in-Aid for Research on Hepatitis from Japan Agency for Medical Research and development","award":["1"],"award-info":[{"award-number":["1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00535-015-1108-6","type":"journal-article","created":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T10:26:51Z","timestamp":1437733611000},"page":"1145-1151","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice"],"prefix":"10.1007","volume":"50","author":[{"given":"Yugo","family":"Kai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Nakabori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsugiko","family":"Oze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suemizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,25]]},"reference":[{"key":"1108_CR1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","volume":"58","author":"A Aghemo","year":"2013","unstructured":"Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58:428\u201338.","journal-title":"Hepatology"},{"key":"1108_CR2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-014-0279-4","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM. Daclatasvir\u00a0+\u00a0asunaprevir: first global approval. Drugs. 2014;74:1559\u201371.","journal-title":"Drugs"},{"key":"1108_CR3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216\u201324.","journal-title":"N Engl J Med"},{"key":"1108_CR4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1108_CR5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597\u2013605.","journal-title":"Lancet"},{"key":"1108_CR6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646\u201354.","journal-title":"J Hepatol"},{"key":"1108_CR7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"1108_CR8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u201393.","journal-title":"N Engl J Med"},{"issue":"6","key":"1108_CR9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1108_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2011.01.042","volume":"405","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa M, Kawai K, Mitsui T, et al. The reconstituted \u2018humanized liver\u2019 in TK-NOG mice is mature and functional. Biochem Biophys Res Commun. 2011;405:405\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"1108_CR11","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1128\/AAC.03847-14","volume":"58","author":"AM Lam","year":"2014","unstructured":"Lam AM, Edwards TE, Mosley RT, et al. Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance. Antimicrob Agents Chemother. 2014;58:6861\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1108_CR12","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","volume":"57","author":"KA Wong","year":"2013","unstructured":"Wong KA, Worth A, Martin R, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333\u201340.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1108_CR13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40121-014-0052-8","volume":"4","author":"J Friborg","year":"2014","unstructured":"Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2014;4(1):137\u201344.","journal-title":"Infect Dis Ther"},{"key":"1108_CR14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192\u2013206.","journal-title":"J Hepatol"},{"key":"1108_CR15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1586\/14787210.2014.925800","volume":"12","author":"T Takehara","year":"2014","unstructured":"Takehara T. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. Expert Rev Anti Infect Ther. 2014;12:909\u201317.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1108_CR16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146:736\u201343 (e731).","journal-title":"Gastroenterology"},{"key":"1108_CR17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878\u201387.","journal-title":"N Engl J Med"},{"key":"1108_CR18","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","volume":"54","author":"RA Fridell","year":"2011","unstructured":"Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924\u201335.","journal-title":"Hepatology"},{"key":"1108_CR19","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359\u201368.","journal-title":"Antimicrob Agents Chemother"},{"key":"1108_CR20","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","volume":"59","author":"ES Svarovskaia","year":"2014","unstructured":"Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666\u201374.","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-015-1108-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1108-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:40:16Z","timestamp":1559083216000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-015-1108-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,25]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1108"],"URL":"https:\/\/doi.org\/10.1007\/s00535-015-1108-6","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,25]]}}}